1. PHARMACEUTICAL

2. PRIYANKA RAVAL
ROLL NO:17070

3. INTRODUCTION
Science dealing with
collection, preparation, and
standardization of DRUGS,
derives its name from the Greek
root PHARMAKON, a drug
a company that makes
and sells
pharmaceuticals

4. Pharmacy began in Van Established the H.T. Gould &
Diemen's Land with the supply of Co. Homeopathic Pharmacy in Hobart in
medicines by 1881
military surgeons and dispensers
Formal separation of medicine and
As the number of free settlers pharmacy came about when the Pharmacy
grew, traders with ‘chemical Act was passed in 1908
knowledge' brought in shipments
of medicines and chemicals
Most medicines were compounded
mixtures of natural ingredients until the
The first was Michael Bates
who, in 1825, established a early 1900s, when the advent of patent
business as medicines and manufactured tablets such
'PHARMACOPOLIST, Chemist as ASPIRIN AND PHENACETIN
and Druggist' in Launceston
The synthesis of antibiotics and
Hatton & Laws Chemists, one of antipsychotics revolutionized drug
the oldest pharmacy businesses treatment in the 1940s and 1950s
still operating in Australia
In 1978 Pharmacy moved to the
Chemists were licensed by laws University of Tasmania, where it came to
enacted in 1837, 1840 and 1842 be ranked as one of the best pharmacy
courses in Australia.

5. INVOLVEMENT OF
PHARMACEUTICALS IN INDIAn
SECTOR
Pharmaceuticals
Other

6. BIOTECHNOLOGY
PHARMAC-
TAXES OF EUTICAL
PHARMAC- MARKETIN
EUTICALS G
PHARMACEUTICALS
products
sold to the
Government consumers
support & &
Foreign investment Consumer prefer
products

7. FURTHER WILL BE CONTINUED
BY
MAYUR .S. AHUJA
ROLL no:17091

8. -PHARMACEUTICALS-
BIOTECHNOLOGY

9. OVERVIEW - PHARMACEUTICALS
Fastest growing
pharmaceuticals market.
12% annually in last 5 years.
Pharmaceuticals market was
worth Rs. 66,400 crore in
2007-08, the domestic retail
market is expected to reach
around USD 13 billion by
2012.

10. EXPORTS
By 2012, exports are
Expected to touch USD 23.5
Billion(RS. 94,000 crore ).
India is the worlds fifth-
largest producer of bulk
drugs.

11. GLOBAL PHARMACEUTICAL
COMPANIES ATTRACTED TO INDIA
Since January 2005, about 15
patented products have been
launched in the country.

12. OVERVIEW - BIOTECHNOLOGY
India is among top 12 biotech
markets globally.
India ranks third in Asia-Pacific
region, after Japan n Korea.

13. THE PHARMACEUTICAL HUB

14. FURTHER WILL BE CONTINUED
BY
Akshay rane
ROLL no:17066

15. Pharmaceuticals products
sold to the consumers
&
Consumer prefer products.
 Selling of products to the consumer is depend
upon some Demographic changes :-
Consumer’s healthcare
Segments:-
1. Personal care
2. Scientifically based

16. 1. Personal care:-
 Companies Persuade Consumers that their
products are testy and healthy.
 Promise to deliver health benefits in
pharmaceuticals products.
 Companies provides specific health needs or
increase some dimension of performance.
 Pharmaceuticals companies expands their
business beyond the over the counter market
(expand business on large scale).

17. 2. Scientific based care:-
 Companies encouraging peoples that their
products are scientifically based.
 Companies focusing on growth and profitability.
 E.g.. Nestle company starts consumer health
business.
 Product should be organize or manage by experts
persons.

20. Consumer prefer products
depends upon:-
 Increased focus on Public health.
 Increased consumers spending.
 New spending due to increased in population.

21. FURTHER WILL BE
CONTINUED BY
Brijesh yadav
ROLL no:17088

22. PHARMACEUTICAL MARKETING
Pharmaceutical marketing, sometimes called
medico-marketing or pharma marketing in some
countries, is the business of advertising or
otherwise promoting the sale of pharmaceuticals
or drugs. There is some evidence that marketing
practices can negatively affect both patients and
the health care profession. Many countries have
measures in place to limit advertising
by pharmaceutical companies.

23. . Marketing of legitimate medications, such as pain
relievers or allergy medicine, has also long been
practiced, although, until recently, mass marketing of
prescription medications has been rare. It was long
believed that since doctors made the selection of
drugs, mass marketing was a waste of resources;
specific ads targeting the medical profession were
thought to be cheaper and just as effective. An
important part of these efforts was marketing to
medical students.

24. In the United States, marketing and distribution of
pharmaceuticals is regulated by the Federal
Food, Drug, and Cosmetic Act and the Prescription
Drug Marketing Act, respectively. Food and Drug
Administration (FDA) regulations require all
prescription drug promotion to be truthful and not
misleading, based on "substantial evidence or
substantial clinical experience",

25. SUPPLY CHAIN
MANUFACTURER
CNF
DISTRIBUTING AGENTS
MEDICAL SHOPS
CONSUMER

26. FREE SAMPLES
Free samples have been shown to affect physician
prescribing behaviour.
It is argued that a benefit to free samples is the “try it
before you buy it” approach. Free Samples give
immediate access to the medication and the patient
can begin treatment right away. Also, it saves time
from going to a pharmacy to get it filled before
treatment begins.free samples allows you to find
which dose and brand of medication works best
before having to spend money on a filled prescription
at a pharmacy.

27. TOP COMPANIES
RANK COMPANY
1 ABBOT INDIA
2 RANBAXY
3 DR.REDDY
LABROTERY
4 AUROBINDO
5 CIPLA

28. TOTAL EXPENDITURE
THE PHARMACEUTICLE INDUSTRY IN INDIA STANDS
THIRD IN THE WORLD IN CASE OF SALES.
ACCORDING TO DEPARTMENT OF
PHARMACEUTICLE ,MINISTERY OF CHEMICLE &
FERTILIZER THE TOTL TURNOVER OF INDIAS
PHARMACEUTICLE INDUSTRY IN 2008-09 WAS
21.04 BILLION.WHILE THE DOMESTIC MARKET WAS
12.26 MILLION.THE EXPENES OF SAME NOW AT
2012 IS 19.22 MILLION.

29. 2008 in Canada $1.7 billion a year was spent
marketing drugs to physicians and in the United
States $21 billion were spent in 2008. In 2011
money spent on pharmaceutical marketing in the US
was estimated at $29.9 billion with one estimate as
high as $57 MILLION.

30. REGULATION & FRAUD
MISLABELLING
HIGH PRICES
LOW LIFE SPAN
SIDE EFFECTS
LIMITED TEMPERATURE
DRUGS SCAM
FALSE PROMOTION.
BOUNDLESS EXPENSIVE.

31. FRAUDS
COMPANY SETTLMENT FRAUDS
GLAXOSMITH 3 BILLION FALSE
PROMOTON
ELI 1.4 BILLION FALSE
PROMOTON
TAP 875 MILLION MEDICARE
FRAUD
SERONO 704 MILLION POOR MANF.

32. FURTHER WILL BE CONTINUED
BY
Kamelshwaran.n
ROLL no:17052

33. Governments Support and
Foreign Investments in
Pharmaceutical Industries
in India

34. Comparison with the U.S.
The Indian biotech sector parallels that of the U.S. in
many ways. Both are filled with small start-ups while the
majority of the market is controlled by a few powerful
companies. Both are dependent upon government grants
and venture capitalists for funding because neither will
be commercially viable for years. Pharmaceutical
companies in both countries have recognized the
potential effect that biotechnology could have on their
pipelines and have responded by either investing in
existing start-ups or venturing into the field
themselves.[36] In both India and the U.S., as well as in
much of the globe, biotech is seen as a hot field with a lot
of growth potential.

36. Relationship with IT
Many analysts have observed that the hype around the biotech sector mirrors
that of the IT sector. Biotech colleges have been popping up around the
country eager to service the pools of students that want to take advantage of
a growing industry. The International Finance Commission, the private
investment arm of the World Bank, called India the “centerpiece of IFC’s global
biotech strategy.” Of the $110 million invested in 14 biotech projects
investment globally, the IFC has given $43 million to 4 projects in India.
According to Dr. Manju Sharma, former director of the Department of
Biotechnology, the biotech industry could become the “single largest sector
for employment of skilled human resource in the years to come.”British Prime
Minister Tony Blair was similarly impressed, citing the success of India’s
biotech industry as the reason for his own country’s own biotech
opportunities. Malaysia is also looking to India as an example for growing its
own biotech industry.

37. Government support
The Indian government has been very supportive. It established the
Department of Biotechnology in 1986 under the Ministry of Science
and Technology. Since then, there have been a number of
dispensations offered by both the central government and various
states to encourage the growth of the industry. India’s science
minister launched a program that provides tax incentives and grants
for biotech start-ups and firms seeking to expand and establishes
the Biotechnology Parks Society of India to support ten biotech
parks by 2010. Previously limited to rodents, animal testing was
expanded to include large animals as part of the minister’s initiative.
States have started to vie with one another for biotech business, and
they are offering such goodies as exemption from VAT and other
fees, financial assistance with patents and subsidies on everything
ranging from investment to land to utilities.

38. Foreign investment
The government has also taken steps to encourage foreign
investment in its biotech sector. An initiative passed earlier
this year allowed 100% foreign direct investment without
compulsory licensing from the government. In April, a
delegation headed by the Kapil Sibal, the minister of
science and technology and ocean development, visited
five cities in the U.S. to encourage investment in India, with
special emphasis on biotech. Just two months later, Sibal
returned to the U.S. to unveil India’s biotech growth
strategy at the BIO2005 conference in Philadelphia. 100%of
fdi is allowed in India.

39. Challenges
The biotech sector faces some major challenges in its quest for
growth. Chief among them is a lack of funding, particularly for
firms that are just starting out. The most likely sources of funds are
government grants and venture capital, which is a relatively young
industry in India. Government grants are difficult to secure, and
due to the expensive and uncertain nature of biotech
research, venture capitalists are reluctant to invest in firms that
have not yet developed a commercially viable product. As
previously mentioned, India hopes to solve its funding problem by
attracting overseas investors and partners. Before these potential
saviors will invest significant sums in the industry, however, there
needs to be better scientific and financial accountability. India is
slowly working towards these goals, but it will be a while before
they are up to the standards of Western investors.

40. FURTHER WILL BE CONTINUED
BY
Abhiyog patil
ROLL no:17056

41. TAXES OF PHARAMACEUTICALS
• GOODS AND SERVICE TAX(GST):-
INTRODUCTION
DUAL GST IN INDIA
IMPACT ON PHARMACEUTICAL INDUSTRY:-
1. Procurement
2. Manufacture
3. Sales and distribution
4. Pricing
5. Services
6. IT changes

42. • DIRECT TAX:-
Tax structure
Incentives to pharmaceutical sectors
• INDIRECT TAXES:-
Custom duty
Central excise duty
Value added Tax and central sales tax

43. Table Comparing Prices
DRUGS MFG BY PRICES INCREASE IN
TAX VALUE
(approx)
RISPERIDONE Johnson &
(Risperdal) Johnson 366 491 34.15 %
RISEDRONATE Cipla
(Risofos) 166 221 33.13%
CLOPIDOGREL Zydus
(Noklot) 111 167 50.45%
PREGABALIN Intas Pharma
(Pregabit) 98 154 57.14%

44. GRAPHICAL IMPLEMENTATION
34.15 % 33.13 % 50.45 % 57.14 %
450
400 491
366
350
300
Prices
250 221
2010
200 166 167 154 2012
150
111 98
100
50
0
Risperidone Risedronate Clopidogrel Pregabalin
DRUGS

46. THANK YOU